<DOC>
	<DOCNO>NCT02028975</DOCNO>
	<brief_summary>Animal study show stimulation lingual lipid-receptor , CD 36 , accompany rapid secretion hormone digestive tract ( incretines ) . We aim determine healthy human whether orosensory perception fatty acid follow modification plasma level digestive tract hormone ( cholecystokinin , GIP , GLP-1 , secretin , pancreatic peptide , peptide YY , insulin ) metabolic marker adipose tissue ( leptin , ghrelin , adiponectin ) . We also aim determine whether hormonal response induce orosensory stimulation lipid modify : - patient type 2 diabetes - obese non-diabetic patient We expect show increase biological marker biological , particularly certain digestive hormone Pancreatic polypeptide , GIP , GLP-1â€¦after stimulation lingual lipid receptor , CD36 . We also determine whether response modify patient type 2 diabetes obese non-diabetic patient . We also wish measure subject ' gustatory detection threshold fatty acid ( linoleic acid ) , determine whether relationship orosensory perception threshold linoleic acid physiological status subject . In order achieve , threshold healthy subject compare threshold obese diabetic subject . Expected result : threshold detection linoleic acid healthy subject low obese diabetic patient .</brief_summary>
	<brief_title>Search Biological Markers Orosensory Perception Fatty Acids Healthy Subjects Possible Modifications Patients With Type 2 Diabetes Obese Non-diabetic Patients .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>person provide write consent Healthy volunteer : Men &gt; 18 year 19 &lt; BMI &lt; 25 kg.m2 Fasting triglyceridemia &lt; 1.50 g/l Fasting glycemia &lt; 1.10 g/l Without regular medical treatment Patients type2 diabetes : Men &gt; 18 year type 2 diabetes ( fast glycemia &gt; 7 mmol/l diagnosis ) treat diet diet + oral antidiabetic ( metformin , and/or insulinsecretion agent [ hypoglycemic sulphonamides , glinides ] and/or glitazones and/or acarbose ) Stable oral antidiabetic treatment 3 month Obese nondiabetic patient : Men &gt; 18 year BMI 30 kg.m2 Fasting glycemia &lt; 1.10 g/l HbA1c &lt; 6.0 % Absence treatment hypoglycemic agent ( include benfluorex ) Absence medical treatment obesity Absence history surgery obesity ( band , bypass ) gastric stimulator ( type Tantalus ) Persons cover national health insurance Smokers , smoke cessation within 3 month precede inclusion Persons eat disorder : Severe digestive disease ( enteropathy absorption disorder , inflammatory digestive disease ) Pancreatic insufficiency History pancreas surgery Type 1 diabetes Renal insufficiency Hepatic insufficiency Treatment proton pump inhibitor , insulin , GLP1 analogues , DPP4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>